关键词：炎症性肠疾病；自体免疫疾病；炎症；抗炎甾体类产品；免疫抑制剂
摘 要：Inflammatory bowel diseases are a group of autoimmune conditions such as Crohn's disease and ulcerative colitis that cause chronic inflammation in any part of or the entire GI tract. Ulcerative colitis generally causes inflammation and leads to the formation of ulcers in the innermost lining of the colon and the rectum of the patient. Crohn's disease causes inflammation of the inner lining of the GI tract resulting in ulceration in various areas of the tract such as the large intestine and small intestine, or both. Severe persistent diarrhea, abdominal cramps and pain, rectal bleeding, fatigue, and weight loss are major symptoms of both Crohn's disease and ulcerative colitis. Inflammatory bowel disease can also prove to be life threatening for patients. It is a chronic medical condition that has no permanent cure and demands lifetime treatment and management. The preferred treatment options include anti-inflammatory steroidal products and immunosuppressive agents such as TNF-α inhibitors.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market overview

03.2 Product offerings

04. Market Research Methodology

04.1 Market research process

04.2 Research methodology

05. Introduction

06. Disease Overview: Crohn's Disease

06.1 Understanding the disease

06.2 Etiology

06.2.1 Autoimmune reaction

06.2.2 Genes

06.2.3 Environment

06.3 Stages of Crohn's disease

06.4 Epidemiology

06.4.1 Worldwide prevalence of Crohn's disease

06.4.2 US

06.4.3 UK

06.5 Symptoms

06.5.1 Diarrhea

06.5.2 Fever and fatigue

06.5.3 Abdominal pain and cramping

06.5.4 Perianal disease and blood in stool

06.5.5 Reduced appetite and weight loss

06.6 Diagnosis and testing

06.6.1 Early tests and exams

06.6.2 Endoscopy and biopsy

06.6.3 Chromoendoscopy

06.6.4 Small intestinal imaging

06.7 Treatment

06.7.1 Medication

06.7.2 Diet and nutrition

06.7.3 Surgery

07. Disease Overview: Ulcerative Colitis

07.1 Understanding the disease

07.2 Etiology

07.2.1 Autoimmune reaction

07.2.2 Genetics

07.2.3 Environmental factors

07.3 Prognosis

07.4 Epidemiology

07.4.1 Global

07.4.2 UK

07.4.3 US

07.5 Symptoms

07.6 Diagnosis and testing

07.7 Treatment

07.7.1 Medical treatment options

07.7.2 Surgical procedures

08. Pipeline Portfolio

08.1 Crohn's disease pipeline landscape

08.1.1 Some emerging therapeutic options

08.2 Ulcerative colitis pipeline landscape

09. Market Landscape

09.1 Global inflammatory bowel disease market

09.2 Market size and forecast

09.3 Inflammatory bowel disease market in US

09.3.1 Market size and forecast

09.4 Inflammatory bowel disease market in EU

09.4.1 Market size and forecast

09.5 Inflammatory bowel disease market in Japan

09.5.1 Market size and forecast

09.6 Five forces analysis

10. Market Segmentation by Type of Disease

10.1 Crohn's disease

10.2 Ulcerative colitis

11. Global Crohn's Disease Market

11.1 Market size and forecast

11.2 Crohn's disease market in US

11.2.1 Market size and forecast

11.3 Crohn's disease market in Japan

11.3.1 Market size and forecast

12. Global Ulcerative Colitis Market

12.1 Market size and forecast

13. Market Segmentation by Drug Class

14. Market Segmentation by Type of Molecule

14.1 Biologics

14.2 Small molecules

15. Market Segmentation by Dosage Form

15.1 Solid

15.2 Liquid

16. Market Segmentation by Route of

Administration

16.1 Oral

16.2 Parenteral

17. Geographical Segmentation

17.1 Segmentation of global inflammatory market by

geography

17.2 Segmentation of global Crohn's disease and

ulcerative colitis markets by geography

17.3 Segmentation of global Crohn's disease market

by geography

17.4 Segmentation of global ulcerative colitis market

by geography

18. Key Leading Countries

18.1 Key leading countries 2014

18.2 Key leading countries 2019

18.3 US

18.4 Japan

19. Buying Criteria

20. Market Growth Drivers

21. Drivers and their Impact

22. Market Challenges

23. Impact of Drivers and Challenges

24. Market Trends

25. Trends and their Impact

26. Vendor Landscape

26.1 Competitive scenario

26.1.1 Key news

26.1.2 Mergers and acquisitions

26.2 Market share analysis 2014

26.2.1 Competitive assessment of top drugs for inflammatory

bowel disease

26.2.2 AbbVie

26.2.3 Janssen Pharmaceuticals

26.2.4 Merck

26.2.5 Biogen Idec

26.2.6 UCB

26.2.7 Shire

26.3 Other and future prominent vendors

27. Key Vendor Analysis

27.1 AbbVie

27.1.1 Key facts

27.1.2 Business overview

27.1.3 Product segmentation by revenue 2013

27.1.4 Product segmentation by revenue 2012 and 2013

27.1.5 Sales by geography

27.1.6 Business strategy

27.1.7 Key developments

27.1.8 SWOT analysis

27.2 Biogen Idec

27.2.1 Key facts

27.2.2 Business overview

27.2.3 Business segmentation by revenue 2013

27.2.4 Geographical segmentation by revenue 2013

27.2.5 Business strategy

27.2.6 Key developments

27.2.7 SWOT analysis

27.3 Janssen Pharmaceuticals

27.3.1 Key facts

27.3.2 Business overview

27.3.3 Recent developments

27.3.4 SWOT analysis

27.4 Merck

27.4.1 Key facts

27.4.2 Business overview

27.4.3 Business segmentation by revenue 2013

27.4.4 Business segmentation by revenue 2012 and 2013

27.4.5 Sales by geography

27.4.6 Business strategy

27.4.7 Key developments

27.4.8 SWOT analysis

27.5 Shire

27.5.1 Key facts

27.5.2 Business overview

27.5.3 Geographical segmentation by revenue 2013

27.5.4 Business strategy

27.5.5 Recent developments

27.5.6 SWOT analysis

27.6 UCB

27.6.1 Key facts

27.6.2 Business overview

27.6.3 Product segmentation by revenue 2013

27.6.4 Product segmentation by revenue 2012 and 2013

27.6.5 Geographical segmentation by revenue 2013

27.6.6 Business strategy

27.6.7 Recent developments

27.6.8 SWOT analysis

28. Other Reports in this Series